Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06144424 · ClinicalTrials.gov registry record · Phase 2
Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of EP262 in Subjects With Atopic Dermatitis
A Phase 2 study, sponsored by Escient Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 32
- Enrollment target
NCT06144424: Completed Phase 2 study, sponsored by Escient Pharmaceuticals.
NCT06144424 is a Phase 2 study that has completed, run by Escient Pharmaceuticals. The registered enrollment target is 32 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (76% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06144424, a Phase 2 study, has completed, sponsored by Escient Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 32 participants
- Enrollment target
Study Summary
This Phase 2a trial will evaluate the effects of EP262 in subjects with atopic dermatitis
Primary Outcome
An AE is defined as any untoward medical occurrence in a participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable or unintended sign (including a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product. A TEAE is defined as an adverse event (AE) with an onset after the first dose of study drug or
Interventions
- DRUG Placebo
- DRUG Oral EP262
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2023-10-25 |
| Est. Completion | 2024-07-31 |
| Phase | Phase 2 |
What the finished NCT06144424 record still lists
NCT06144424 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 32 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (76% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT06144424 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06144424 about?
NCT06144424 is a clinical study titled "Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of EP262 in Subjects With Atopic Dermatitis". This Phase 2a trial will evaluate the effects of EP262 in subjects with atopic dermatitis
What is the current status of trial NCT06144424?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 32 participants. The study started on 2023-10-25. Estimated completion is 2024-07-31.
What interventions are being tested in trial NCT06144424?
The interventions under investigation include: Placebo (DRUG), Oral EP262 (DRUG).
Who is sponsoring clinical trial NCT06144424?
This trial is sponsored by Escient Pharmaceuticals, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06144424's enrollment target sits among peer trials
32 1563rd of 2000 higher than 423 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02445781 · 32 participants · Early Phase 1
Differing Levels of Hypoglycemia
- NCT02792270 · 32 participants · NA
Caloric Restriction In Sarcoma Patients Treated With Pre-Operative RT
- NCT03068910 · 32 participants · Early Phase 1
Hyperandrogenemia and Altered Day-night LH Pulse Patterns
- NCT03208868 · 32 participants · NA
Leucine Enriched Essential Amino Acid Mixture to Reverse Muscle Loss in Cirrhosis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI